Literature DB >> 19851348

Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.

Bertram Pitt1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19851348     DOI： 10.1038/nrcardio.2009.175

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  8 in total

1.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

2.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

Review 3.  Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.

Authors:  Murray Epstein
Journal:  Am J Med       Date:  2006-11       Impact factor: 4.965

4.  Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

Authors:  David N Juurlink; Muhammad M Mamdani; Douglas S Lee; Alexander Kopp; Peter C Austin; Andreas Laupacis; Donald A Redelmeier
Journal:  N Engl J Med       Date:  2004-08-05       Impact factor: 91.245

5.  Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

Authors:  Nicola C Edwards; Richard P Steeds; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  J Am Coll Cardiol       Date:  2009-08-04       Impact factor: 24.094

Review 6.  Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Authors:  James R Sowers; Adam Whaley-Connell; Murray Epstein
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

Review 7.  Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist.

Authors:  Frances McManus; Gordon T McInnes; John M C Connell
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-01

8.  Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease.

Authors:  Richard A Preston; David Afshartous; Dyal Garg; Sergio Medrano; Alberto B Alonso; Rolando Rodriguez
Journal:  Hypertension       Date:  2009-03-23       Impact factor: 10.190
  8 in total
  2 in total

1.  The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.

Authors:  Nicola C Edwards; Richard P Steeds; Colin D Chue; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

2.  Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.

Authors:  Nathan R Hill; Daniel Lasserson; Ben Thompson; Rafael Perera-Salazar; Jane Wolstenholme; Peter Bower; Thomas Blakeman; David Fitzmaurice; Paul Little; Gene Feder; Nadeem Qureshi; Maarten Taal; Jonathan Townend; Charles Ferro; Richard McManus; Fd Richard Hobbs
Journal:  Trials       Date:  2014-05-08       Impact factor: 2.279
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.